Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
PITTSBURGH, Dec. 5, 2022 – Jeune Aesthetics, a subsidiary of Krystal Biotech (NASDAQ: KRYS), announced its participation in the Cantor Fitzgerald Medical and Aesthetic Dermatology Conference on December 8 in Miami.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PITTSBURGH, Dec. 5, 2022 – Jeune Aesthetics, a subsidiary of Krystal Biotech (NASDAQ: KRYS), announced its participation in the Cantor Fitzgerald Medical and Aesthetic Dermatology Conference on December 8 in Miami. Senior VP September Riharb will join a panel titled Distraction or Destruction: What’s New/Next in the Industry at 11:00 am ET. The management team will also engage in investor meetings that day. Jeune focuses on reversing aging skin through a gene-delivery platform.
Details
News Market Reaction – KRYS
The recorded move for KRYS in the trading session of this news was -2.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced that the company will participate in the investor-focused Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference, which is taking place in Miami on December 8.
September Riharb, Senior Vice President of Marketing for Jeune, will participate in an aesthetic dermatology panel on December 8 at 11:00 am ET, Distraction or Destruction: What’s New/Next in the Industry. The Jeune and Krystal management team will also attend investor meetings on December 8.
About Jeune Aesthetics, Inc.
Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin. For more information, please visit http://www.jeuneinc.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The Company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. Headquartered in Pittsburgh, Pennsylvania, the Company is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.
CONTACT:
Investors and Media:
Meg Dodge
Krystal Biotech
mdodge@krystalbio.com
Source: Krystal Biotech, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.